Investment Thesis
- Requirement for ultrasound disinfection. Ultrasound transducers must be disinfected between patients to prevent cross-infection. Trophon EPR is a significant improvement above traditional methods (soak, spray, wipe or other manual reprocessing/disinfection method). For instance, traditional soaking takes ~25 minutes versus Trophon which takes ~7-8 minutes to disinfect ultrasound probes.
- Potential addressable installed base of ~120,000 Trophon EPR units globally (~40,000 in the US, Europe and Rest of World each).
- New guidelines and regulation drive pathways to reinforce requirements for high level disinfection. For instance, new guidelines in Australia and New Zealand setting Trophon as the standard in high level disinfection.
- Continued growth in North America to be driven by its direct sales team with adoption remaining strong and Trophon becoming the standard of care.
- Large and credible distribution partner is retained in GE Healthcare with demand for safety inventory.
- Managed Equipment Service business model (MES) in the UK overcoming capital budget constraints by clients.
- Progress with geographic expansion.
- Strong balance sheet to support growth strategy.
Key Risks
- Competitive pressures as potential entrants enter the market.
- Non-receptive markets where NAN’s product is considered overkill compared to traditional disinfection methods such as using sterilised wipes.
- Key customer risk as one customer is NAN’s largest customer
- Product faults or incidents where recalls are required.
- Adverse foreign currency movements in AUD/USD.
- Poor execution of R&D with no progress.
- Nature of business makes it prone to easily reaching a natural penetration rate, where growth becomes subdued.
1H22 Results Highlight
- Revenue of $60.6m, up +41%, driven by strong growth with capital revenue of $19.0m, up +102%, and consumables and service revenue of $41.6m, up +23%.
- Global installed base up +12%.
- Continued investment in the strategic growth agenda resulted in operating expenses of $42.7m, up +29%.
- Operating profit before tax of $3.3m, significantly improved from the $0.2m in the pcp.
- NAN has no debt and its cash position continues to provide a strong foundation to support its growth plans – 1H22 free cash flow reflects net outflow of $3.8m with Cash and cash equivalents of $92.0m at 31 December 2021.
- R&D investment of $10.7m, up +41%, with a focus on NAN’s new endoscope reprocessing product platform, Nanosonics Coris.
Company Profile
Nanosonics Ltd (NAN) is an ASX-listed company which focuses on developing and commercialising infection control devices. NAN’s first device, the trophon® EPR is a proprietary automated device for low temperature, high level disinfection of ultrasound probes. The device is approved for sale across major markets including, Australia and New Zealand, US, Europe, Japan, Hong Kong, and South Korea. The trophon® EPR is sold through distributors including GE Healthcare, Philips, Samsung, Siemens Toshiba and Miele Professional.
(Source: BanyanTree)
General Advice Warning
Any advice/ information provided is general in nature only and does not take into account the personal financial situation, objectives or needs of any particular person.